Dr. David J Izbrand is a Abilene, Texas based male Ophthalmologist who is specialized in Ophthalmology. Active license number of Dr. David J Izbrand is H2486 for Ophthalmology in Texas. Dr. David J Izbrand is medically trained to diagnose, monitor and medically or surgically treat all ocular and visual disorders. This includes problems affecting the eye and its component structures, the eyelids, the orbit and the visual pathways. In so doing, patients can be prescribed vision services, including glasses and contact lenses.
Complete Profile:
Dr. David J Izbrand speciality, credentials, practice address, contact phone number and fax are as below.
Patients can directly walk in or can call on the below given phone number for appointment.
Specialization:
Ophthalmology
Credentials:
M.D.
Gender:
Male
Practice Address:
1750 Pine St, Abilene, Texas, 79601-3044
Phone:
325-677-2741
Fax:
325-676-1803
Professional Identification Codes:
NPI number stands for National Provider Identifier which is a unique 10-digit identification number issued to health care providers in the United States by the Centers for Medicare and Medicaid Services (CMS).
NPI details are as mentioned below.
NPI Number:
1639145410
NPI Enumeration Date:
23 Feb, 2006
NPI Last Update On:
12 Jul, 2007
Medical Licenses:
Doctors can have one or more medical licenses for different specialities in the same state or different states. Related medical licenses for Dr. David J Izbrand are as mentioned below.
License Number
Specialization
State
Status
H2486
Ophthalmology
Texas
Primary
Business Mailing Address:
Business mailing address can be used for mailing purpose only, for visiting purpose patients need to refer above mentioned address.
Address:
1750 Pine St, Abilene, Texas
Zip:
79601-3044
Phone Number:
325-677-2741
Fax Number:
325-676-1803
Patients can reach Dr. David J Izbrand at 1750 Pine St, Abilene, Texas or can call to book an appointment on 325-677-2741. Data of this site is collected from Medicare & Medicaid Services (CMS) and NPPES. Last updated on 09 December, 2024.